Magnesium Aspartate Hydrochloride Research Articles

Oral supplementation of magnesium aspartate hydrochloride in horses with Equine Metabolic Syndrome

Oral supplementation of magnesium aspartate hydrochloride in horses with Equine Metabolic Syndrome

Oral supplementation of magnesium aspartate hydrochloride in horses with Equine Metabolic Syndrome

Oral supplementation of magnesium aspartate hydrochloride in horses with Equine Metabolic Syndrome

Influence of the magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration of the fetal circuit under in vitro perfusion of human placenta

Objectives Magnesium aspartate hydrochloride (Magnesiocard ®, Mg–Asp–HCl) is proposed as a substitute of magnesium sulfate for the treatment of preeclampsia and premature labor. After an i.v. administration of a dose equivalent to that used in the treatment of preeclampsia to nonpregnant volunteers, a 10-fold increase of aspartic acid (Asp) over the physiological level was observed. Animal experiments have demonstrated that highly increased fetal levels of acidic amino acids such as Asp could be associated with neurotoxic damage in the fetal brain. The influence of such an elevation of Asp concentration in the maternal circuit on the fetal level, using the in vitro perfusion model of human placenta, was investigated. Study design After a control phase (2 h), a therapeutic dose of Mg combined with Asp (Magnesiocard ®, Mg–Asp–HCl) was applied to the maternal circuit approaching 10 times the physiological level of Asp. The administration was performed in two different phases simulating either a peak of maximum concentration (bolus application, 2 h) or a steady state level (initially added, 4 h). Results In four experiments, during experimental phases (6 h) a slow increase in concentration in the fetal circuit was seen for Mg, AIB (alpha-aminoisobutyric acid, artificial amino acid) and creatinine confirming previous observations. In contrast, no net transfer of Asp across the placenta was seen. A continuous decrease in the concentration of Asp on both maternal and fetal side suggests active uptake and metabolization by the placenta. Viability control parameters remained stable indicating the absence of an effect on placental metabolism, permeability and morphology. Conclusion Elevation of Asp concentration up to 10 times the physiological level by the administration of Mg–Asp–HCl to the maternal circuit under in vitro perfusion conditions of human placenta has no influence on the fetal level of Asp suggesting no transfer of Asp from the maternal to fetal compartment. Therefore, the administration of Mg–Asp–HCl to preeclamptic patients would be beneficial for the patients without any impact on placental or fetal physiology.

Behaviour, growth performance and pork quality of pigs differing in porcine stress syndrome genotype receiving dietary magnesium aspartate hydrochloride

Frequency of behavioural activities, growth performance and pork quality were determined for pigs with homozygous-normal (NN) or heterozygous-carrier (Nn) genotypes for porcine stress syndrome receiving dietary supplementation of magnesium aspartate hydrochloride (MAH). One hundred and forty-two pigs, 67.2 ± 1.2 kg, were assigned by genotype and gender to one of three dietary treatments. The pigs were fed a conventional cereal-based pelleted diet (Control), supplemented with a long-term, low-level (LL-MAH; 5 mg kg−1 BW for 43 ± 3 d) or short-term, high-level (SH-MAH; 40 mg kg−1 BW for 7 d) of MAH before slaughter. Supplementation of MAH did not significantly affect the behaviour of pigs before or after transport for slaughter with the exception of SH-MAH-fed pigs showing a higher (P < 0.05) frequency of pre-transport aggression. Pigs with the Nn genotype were, in general, more active 1 h before slaughter showing a higher frequency (P = 0.001) of aggression. Average daily gain of LL-MAH-fed pigs was higher (P < 0.05) than for those pigs fed the Control and SH-MAH diets. Pigs receiving both levels of MAH had lower (P < 0.05) longissimus thoracis (LT) muscle lean depth. In terms of pork quality, there were significant diet-by-genotype interactions. For pigs with the NN genotype, SH-MAH caused higher (P < 0.05) ultimate pH, lower muscle temperature and lower shear value of the LT. For pigs with the Nn genotype, MAH at both levels lowered (P < 0.05) glycogen content and subjective structure score of the LT, but ultimate pH, muscle temperature and lactate content were higher (P < 0.05) than those of Controls. Efficacy of MAH supplementation to pigs appears to be highly dependent on diet and genotype. Key words: Pigs, porcine stress syndrome, magnesium, pork

In vitro perfusion of human placenta: Influence of magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration in the fetal circuit

Placental growth hormone (PGH) is the product of the GH-V gene specifically expressed in the syncytiotrophoblast layer of the human placenta. PGH differs from pituitary growth hormone by 13 amino acids. It has high somatogenic and low lactogenic activities. Assays of PGH by specific monoclonal antibodies reveal that in the maternal circulation from 15–20 weeks up to term, PGH gradually replaces pituitary growth hormone which becomes undetectable. It is secreted by the placenta in a non-pulsatile manner. This continuous secretion appears to have important implications for physiological adjustment to gestation and especially in the control of maternal IGF1 levels. PGH secretion is inhibited by glucose in vitro and in vivo, and is significantly decreased in the maternal circulation in cases of pregnancies with intrauterine growth retardation. PGH does not appear to have a direct effect on fetal growth, as this hormone is not detectable in the fetal circulation. However the physiological role of PGH might also include a direct influence on placental development via an autocrine or paracrine mechanism as suggested by the presence of specific GH receptors in this tissue.

A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia

Magnesium aspartate hydrochloride (MgAH) (Magnesiocard, Ciba-Geigy, Summit, NJ, USA) is a magnesium compound designed for oral administration in the treatment of magnesium deficiency. The intent of this randomised trial was to determine if MgAH is able to prevent and/or replenish the cisplatin-induced loss of body stores of magnesium

Magnesium-Aspartate-Hydrochloride Reduces Weight Loss in Heat-Stressed Laying Hens

Two separate experiments were conducted to determine the ability of magnesium aspartate hydrochloride (Mg-Asp-HCl) to antagonize the effects of thermal stress in laying hens. In both experiments, hens were exposed to either a cyclic ambient temperature of 27 C to 35 C (hyperthermic group) or 23 C (control group) for7 days. In Experiment 1, hens were given a single injection of either saline, 40 mg, or 80 mg Mg-Asp-HCl. Experiment 2 hens received a single injection of saline, 40 mg Mg-Asp-HCl, or twice daily injection of 40 mg Mg-Asp-HCl.In both experiments, heat-stressed hens had elevated body temperature and reduced body weight, feed consumption, and circulating mean Mg concentrations. Hyperthermic hens also had reduced egg weights in Experiment 1.A single daily injection of 40 mg of Mg-Asp-HCl significantly reduced body weight loss in heat stressed hens by 41 and 51%, in Experiment 1 and 2, respectively, when compared with heat-stressed hens not receiving Mg-Asp-HCl (controls). The Mg-Asp-HCl treatment did not affect overall feed intake, egg production, or body temperature in either experiment The highest dose of Mg-Asp-HCl (80 mg) elevated circulating magnesium concentrations. A single daily injection of 80 mg of Mg-Asp-HCl or twice daily injections of 40 mg Mg-Asp-HCl did not provide any additional benefit when compared with a single daily dose of 40 mg.The antistress effects of Mg-Asp-HCl are apparent in these experiments as evidenced by the increased body weight of heat-stressed hens. Use of this compound may prove to be beneficial in maintaining the performance characteristics of poultry exposed to elevated ambient temperature.

Magnesium, Kalzium, Hämoglobin, Hämatokrit, Östriol und HPL unter Magnesiumsubstitution in der Schwangerschaft

In a randomised double-blind study 568 women were given orally either 15 mmol magnesium-aspartate hydrochloride per day or aspartic acid as placebo. The outcome of pregnancy was significantly improved in the magnesium group (fewer maternal hospitalisations, reduction in preterm delivery and less frequent referral of newborn to the neonatal intensive care unit). In the 437 patients with regular intake of tablets, haematocrit, haemoglobin and calcium show a decrease up to 20 weeks of gestation (wks) and an increase during the last 8 wks, whereas magnesium stays at a low level. Oestriol and HPL are rising steadily during gestation. In all parameters, no differences were found between the magnesium and placebo group, except for a higher level of oestriol at 33 to 36 wks and a lower level above 36 wks in the magnesium group. Because of the numerous benefits throughout the pregnancy magnesium supplementation is recommended for all pregnancies.

Magnesium dietary intake modulates blood lipid levels and atherogenesis.

In this study, we have examined the effects of variation in dietary Mg on the atherogenic process. Oral supplementation of rabbits fed a high cholesterol diet (1% or 2%) with the Mg salt magnesium aspartate hydrochloride (Magnesiocard) (i) lowers the level of serum cholesterol and triglycerides in normal (25-35%) as well as atherosclerotic (20-40%) animals and (ii) attenuates the atherosclerotic process markedly. In addition, we found that dietary deficiency of Mg augments atherogenesis markedly and stimulates (or activates) macrophages of the reticuloendothelial system. Evidence is presented to indicate that the hypercholesterolemic state may cause the loss of Mg from soft tissues to the serum, thereby masking an underlying Mg deficiency.

Magnesium aspartate HCl and magnesium chloride hexahydrate OROS: Comparative absorption of magnesium in dogs

AbstractThe absorption of magnesium (Mg2+) was measured after oral administration to dogs as a sustained‐release MgCl2·6H2O OROS formulation (MgCl2) or as magnesium aspartate hydrochloride (MAH). The compounds and their respective placebos were given at five 90 min intervals in 7.5 mEq doses (sequential protocol) or in ascending daily doses of 7.5, 22.5, and 45 mEq over 3 days (ascending protocol). Urinary excretion of Mg2+ over 24 hr was significantly increased compared to placebo in the dogs given sequential MgCl2 or MAH and was two‐fold greater in the MgCl2‐treated group compared to the MAH group. Plasma Mg2+ increased more rapidly in the MgCl2‐treated dogs but was identical in both groups 1 hr after the fifth sequential dose. Ascending daily doses of MgCl2 and MAH increased urinary Mg2+ and plasma Mg2+ maximally 2–4 hr after each dose; the magnitude of the effect was dose‐dependent in the MgCl2 group. Sequential doses of MgCl2 or MAH increased urinary Ca2++ excretion by 1.06 and 1 mEq/24 hr respectively while the ascending doses of 22.5 and 45 mEq MgCl2 produced significantly greater urinary Ca2+ excretion than the same doses of MAH. Plasma Ca2+ was not changed by either Mg2+ salt in either dose regimen. The data indicate that Mg2+ is readily absorbed after oral administration in the form of either MgCl2 or MAH, but MgCl2 is absorbed more rapidly. Increased urinary excretion of Ca2+ after MgCl2 or MAH may reflect a displacement of tissue Ca2+ by Mg2+.

A pilot study of magnesium aspartate hydrochloride (Magnesiocard ®) as a mood stabilizer for rapid cycling bipolar affective disorder patients

1. Nine severe rapid cycling manic-depressive patients were treated with a magnesium preparation, Magnesiocard® 40 mEq/day in an open label study for a period up to 32 weeks. 2. Magnesiocard® was found to have clinical results at least equivalent to those of lithium in about 50% of these patients. These results were obtained in an exploratory study and should be interpreted with caution. 3. The possibility that Magnesiocard® could replace or improve the efficacy of lithium as a preventive treatment of manic-depressive illness merits further clinical investigation.

Magnesium supplementation during pregnancy: A double-blind randomized controlled clinical trial

Four hundred young normotensive primigravid women between 13 and 24 weeks' gestation were randomly allocated to one of two study groups. One group received placebo tablets and the other group received 365 mg of elemental magnesium daily (as magnesium aspartate hydrochloride). Three hundred seventy-four patients completed the study, 189 in the placebo group and 185 in the treatment group. There were no significant differences between the two groups regarding serum calcium, uric acid, or electrolyte levels. However, the magnesium-supplemented group had significantly higher magnesium levels at delivery (1.68 +/- 0.03 mg/dl vs. 1.56 +/- 0.03 mg/dl, p less than 0.01). There were no significant differences in either systolic or diastolic blood pressures between both groups either at time of enrollment or at subsequent gestational ages later during pregnancy. Analysis of variance for repeated measurements and Fisher's least significant difference testing indicated a significant increase (p less than 0.01) in blood pressure from the level at the time of enrollment to the level achieved at or beyond 37 weeks' gestation in each group. There were no significant differences between the two groups regarding any of the following parameters: incidences of preeclampsia, fetal growth retardation, preterm labor, birth weight, gestational age at delivery, or number of infants admitted to the special care unit. Magnesium supplementation during pregnancy did not improve pregnancy outcome in our population.

Effects of pH and Anion Substitution on Magnesium Accumulation in Rabbit Aortic Smooth Muscle

The effects of anion substitution, pH and extracellular Mg2+ concentration on 28Mg accumulation were examined in rabbit aortic smooth muscle. Accumulation of 28Mg (expressed as a 28Mg/Mg2+ ratio) was not changed when the concentration of added, nonradioactive MgCl2 was increased from 1.5 to 15.0 mM. The 28Mg efflux rate was increased by added MgCl2 (0.15, 0.5 or 1.5 mM) in a dose-related manner after a similar delay of 5-10 min. Addition of 1.5 mM MgCl2, MgSO4 or magnesium aspartate hydrochloride enhanced 28Mg efflux and inhibited accumulation of 28Mg to the same extent. An increase or decrease in extracellular pH correspondingly increased or decreased 28Mg accumulation. However, the 28Mg efflux rate was not altered when extracellular pH was decreased. Efflux of 28Mg was increased by added 1.5 mM MgCl2 at pH 7.4 but not at pH 5.8. Thus, the net uptake of Mg2+ appears to be proportional to the concentration of extracellular Mg2+ in rabbit aorta. Low external pH decreases 28Mg retention in rabbit aorta by inhibiting the uptake of 28Mg rather than by increasing 28Mg efflux. Effects of added Mg2+ on transmembrane movements of 28Mg are not altered by changes in the associated anion. Extracellular Mg2+ appears to enter the cell and exchange with an intracellularly located pool of 28Mg in the same manner, regardless of whether the accompanying anion is sulfate, chloride or monoaspartate hydrochloride.

Magnesium aspartate hydrochloride attenuates monocrotaline-induced pulmonary artery hypertension in rats.

1. The effect of oral magnesium aspartate hydrochloride on monocrotaline (MCT)-induced pulmonary arterial hypertension was evaluated in rats. 2. A single subcutaneous injection of MCT, a pyrrolizidine alkaloid of plant origin, induces significant morphological changes in pulmonary vessels, pulmonary arterial hypertension and right ventricular hypertrophy in rats by 3 weeks. 3. Two groups of rats (Mg2+ control and Mg2+ + MCT) were started on oral Mg2+ (15.4 g/l magnesium aspartate hydrochloride dissolved in deionized water) 2 weeks before the MCT injection. The rest were given deionized water. At the start of the experiment, the control groups (deionized water and Mg2+) were given normal saline subcutaneously; the other groups (deionized water and Mg2+) were given MCT (60 mg/kg) subcutaneously. 4. Pulmonary artery pressure, right ventricular hypertrophy, lung pathology, organ weights and serum electrolytes were assessed 3 weeks after a single subcutaneous injection of MCT. Seventy-five per cent of the rats treated with MCT and oral Mg2+ (12 out of 16) showed significant reduction in pulmonary arterial hypertension, arterial pathology and right ventricular hypertrophy. 5. Our data indicate that Mg2+ attenuates experimentally induced pulmonary hypertension, possibly either by modulating the intracellular Ca2+ level and/or by directly affecting the pulmonary endothelial cell-smooth muscle cell complex involved in metabolism and maintenance of pulmonary vascular resistance.

Effects of peroral magnesium on plasma and skeletal muscle electrolytes in patients on long-term diuretic therapy

Twenty patients on long-term diuretic therapy for arterial hypertension and/or congestive heart failure were given a supplementary dose of 15 mmol magnesium aspartate hydrochloride per day for 6 months. Nineteen patients, fulfilling the same admission criteria as the treatment group, served as controls. The addition of magnesium aspartate hydrochloride resulted in a significant rise of the cellular potassium and magnesium content and in a significant decrease of both systolic and diastolic blood pressure. It is concluded that supplementation with magnesium aspartate hydrochloride may effectively prevent the diuretic induced disturbances of electrolyte balance.

Additional magnesium therapy in tocolysis: clinico-chemical monitoring parameters

Pregnancy can result in magnesium deficiency, which may precipitate premature labour usually reversed by betamimetic therapy. Inclusion of magnesium in tocolytic therapy is useful for possible reduction of premature labour as well as for cardioprotection. 35 patients with premature labour received Fenoterol + 20 mmol/day magnesium aspartate hydrochloride (Mg-asp-HCl) orally or 30 or 40 mmol/day Mg-asp-HCl and magnesium sulphate (MgSO4) (1:1) i.v. Before and during this therapy, Mg, Ca, K, Na, Cl, creatinin and urea as well as human placental lactogen (HPL) and oestriol (E3) were determined. There were no significant changes in the level of these under oral magnesium therapy. Under intravenous administration, plasma levels of magnesium rose significantly. In the following weeks, the levels dropped in spite of continuing the therapy. The other parameters showed no important changes. Under i.v. administration of 40 mmol/day Mg-asp-HCl, the HPL increase was highly significant. If this could be taken as a hint of better placental function such a positive side effect of magnesium therapy could prove beneficial to "small-for-age" foetuses. Co-medication of 20 mmol/day Mg-asp-HCl (oral) or 40 mmol/day Mg-asp-HCl and MgSO4 (1:1, i.v.) is recommended.